Article

VisiJet expects quick approval for corneal tissue tool

VisiJet Inc. has filed a 510K statement with the FDA for approval of the Epi-Tome, a next-generation ophthalmic surgical tool designed for cutting and separating corneal tissue.

VisiJet Inc. has filed a 510K statement with the FDA for approval of the Epi-Tome, a next-generation ophthalmic surgical tool designed for cutting and separating corneal tissue.

The company has secured worldwide distribution rights from Gebauer Medizintechnik GmbH of Neuhausen, Germany. The product has earned the CE mark and is being sold in Europe and Korea.

VisiJet expects an expedited FDA approval by fall.OT

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.